Glucocorticoids and the Th1/Th2 Balance
ILIA J. ELENKOV,
Corresponding Author
ILIA J. ELENKOV
Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
Address correspondence to: Dr. Ilia J. Elenkov, Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room 2D46, 10 Center Drive, Bethesda, MD 20892. [email protected]Search for more papers by this authorILIA J. ELENKOV,
Corresponding Author
ILIA J. ELENKOV
Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
Address correspondence to: Dr. Ilia J. Elenkov, Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room 2D46, 10 Center Drive, Bethesda, MD 20892. [email protected]Search for more papers by this authorAbstract
Abstract: Evidence accumulated over the last 5-10 years indicates that glucocorticoids (GCs) inhibit the production of interleukin (IL)-12, interferon (IFN)-γ, IFN-α, and tumor necrosis factor (TNF)-α by antigen-presenting cells (APCs) and T helper (Th)1 cells, but upregulate the production of IL-4, IL-10, and IL-13 by Th2 cells. Through this mechanism increased levels of GCs may systemically cause a selective suppression of the Th1-cellular immunity axis, and a shift toward Th2-mediated humoral immunity, rather than generalized immunosuppression. During an immune response and inflammation, the activation of the stress system, and thus increased levels of systemic GCs through induction of a Th2 shift, may actually protect the organism from systemic “overshooting” with Th1/pro-inflammatory cytokines and other products of activated macrophages with tissue-damaging potential. However, conditions associated with significant changes of GCs levels, such as acute or chronic stress or cessation of chronic stress, severe exercise, and pregnancy and postpartum, through modulation of the Th1/Th2 balance may affect the susceptibility to or the course of infections as well as autoimmune and atopic/allergic diseases.
REFERENCES
- 1 Mosmann, T.R. & S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17: 138–146.
- 2 Fearon, D.T. & R.M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50–53.
- 3 Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133–146.
- 4 Elenkov, I.J. & G.P. Chrousos. 1999. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 10: 359–368.
- 5 Chrousos, G.P. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation [see comments]. N. Engl. J. Med. 332: 1351–1362.
- 6 Wilder, R.L. 1995. Neuroendocrine-immune system interactions and autoimmunity. Annu. Rev. Immunol. 13: 307–338.
- 7 Lerner, B.H. 1996. Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949-1961. Ann. Intern. Med. 124: 673–680.
- 8 Von Hertzen, L.C. 2002. Maternal stress and T-cell differentiation of the developing immune system: possible implications for the development of asthma and atopy. J. Allergy Clin. Immunol. 109: 923–928.
- 9 Elenkov, I.J., R.L. Wilder, V.K. Bakalov, et al. 2001. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 86: 4933–4938.
- 10 Beutler, B., N. Krochin, I.W. Milsark, et al. 1986. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232: 977–980.
- 11 Boumpas, D.T., G.P. Chrousos, R.L. Wilder, et al. 1993. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119: 1198–1208.
- 12 Elenkov, I.J., D.A. Papanicolaou, R.L. Wilder & G.P. Chrousos. 1996. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Physicians. 108: 374–381.
- 13 Blotta, M.H., R.H. Dekruyff & D.T. Umetsu. 1997. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J. Immunol. 158: 5589–5595.
- 14 Dekruyff, R.H., Y. Fang & D.T. Umetsu. 1998. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J. Immunol. 160: 2231–2237.
- 15 Wu, C.Y., K. Wang, J.F. McDyer & R.A. Seder. 1998. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161: 2723–2730.
- 16 Kodama, M., H.K. Takahashi, H. Iwagaki, et al. 2002. Effect of steroids on lipopolysaccharide/interleukin 2-induced interleukin 18 production in peripheral blood mononuclear cells. J. Int. Med. Res. 30: 144–160.
- 17 Mysliwiec, J., A. Kretowski, A. Stepien, et al. 2003. Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Int. Immunopharmacol. 3: 549–552.
- 18 Reissland, P. & K.P. Wandinger. 1999. Increased cortisol levels in human umbilical cord blood inhibit interferon alpha production of neonates. Immunobiology 200: 227–233.
- 19 Ramierz, F., D.J. Fowell, M. Puklavec, et al. 1996. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156: 2406–2412.
- 20 Van Der Poll, T., A.E. Barber, S.M. Coyle & S.F. Lowry. 1996. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia—a clinical research center study. J. Clin. Endocrinol. Metab. 81: 3604–3606.
- 21 Shadiack, A.M., C.D. Carlson, M. Ding, et al. Lipopolysaccharide induces substance P in sympathetic ganglia via ganglionic interleukin-1 production. J. Neuroimmunol. 49: 51–58.
- 22 Tabardel, Y., J. Duchateau, D. Schmartz, et al. 1996. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 119: 76–80.
- 23 Gayo, A., L. Mozo, A. Suarez, et al. 1998. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 85: 122–130.
- 24 Naseer, T., E.M. Minshall, D.Y. Leung, et al. 1997. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am. J. Respir. Crit. Care Med. 155: 845–851.
- 25 Bentley, A.M., Q. Hamid, D.S. Robinson, et al. 1996. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am. J. Respir. Crit. Care Med. 153: 551–556.
- 26 Bradding, P., I.H. Feather, S. Wilson, et al. 1995. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am. J. Respir. Crit. Care Med. 151: 1900–1906.
- 27 Batuman, O.A., A. Ferrero, C. Cupp, et al. 1995. Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J. Immunol. 155: 4397–4405.
- 28 Broug-Holub, E. & G. Kraal. 1996. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin. Exp. Immunol. 104: 332–336.
- 29 Moller, B., N. Kukoc-Zivojnov, N. Koyama, et al. 2002. Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells. Inflamm. Res. 51: 457–463.
- 30 Kristo, C., K. Godang, T. Ueland, et al. 2002. Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. Eur. J. Endocrinol. 146: 389–395.
- 31 Karalis, K., H. Sano, J. Redwine, et al. 1991. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254: 421–423.
- 32 Elenkov, I.J., E.L. Webster, D.J. Torpy & G.P. Chrousos. 1999. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann. N.Y. Acad. Sci. 876: 1–11.
- 33 Theoharides, T.C., L.K. Singh, W. Boucher, et al. 1998. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403–413.
- 34 Foreman, J.C. 1987. Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int. Arch. Allergy Appl. Immunol. 82: 366–371.
- 35 Church, M.K., M.A. Lowman, C. Robinson, et al. 1989. Interaction of neuropeptides with human mast cells. Int. Arch. Allergy Appl. Immunol. 88: 70–78.
- 36 Rozniecki, J.J., E. Webster & G.P. Chrousos. 1995. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 136: 5745–5750.
- 37 Elenkov, I.J., R.L. Wilder, G.P. Chrousos & E.S. Vizi. 2000. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52: 595–638.
- 38 Altare, F., A. Durandy, D. Lammas, et al. 1998. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280: 1432–1435.
- 39 Levenstein, S. 1998. Stress and peptic ulcer: life beyond Helicobacter. Brit. Med. J. 316: 538–541.
- 40 Levenstein, S., S. Ackerman, J.K. Kiecolt-Glaser & A. Dubois. 1999. Stress and peptic ulcer disease. J. Am. Med. Assoc. 281: 10–11.
- 41 Clerici, M., M. Bevilacqua, T. Vago, et al. 1994. An immunoendocrinological hypothesis of HIV infection [see comments]. Lancet 343: 1552–1553.
- 42 Kino, T., A. Gragerov, J.B. Kopp, et al. 1999. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. [In Process Citation] J. Exp. Med. 189: 51–62.
- 43 Mirani, M., I. Elenkov, S. Volpi, et al. 2002. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J. Immunol. 169: 6361–6368.
- 44 Cohen, S., D.A. Tyrrell & A.P. Smith. 1991. Psychological stress and susceptibility to the common cold [see comments]. N. Engl. J. Med. 325: 606–612.
- 45 Sainz, B., J.M. Loutsch, M.E. Marquart & J.M. Hill. 2001. Stress-associated immunomodulation and herpes simplex virus infections. Med. Hypotheses 56: 348–356.
- 46 Humbert, M., G. Menz, S. Ying, et al. 1999. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol. Today 20: 528–533.
- 47 Wills-Karp, M. 2001. IL-12/IL-13 axis in allergic asthma. J. Allergy Clin. Immunol. 107: 9–18.
- 48 Marshall, G.D., Jr. & S.K. Agarwal. 2000. Stress, immune regulation, and immunity: applications for asthma. Allergy Asthma Proc. 21: 241–246.
- 49 Von Hertzen, L.C. 2002. Maternal stress and T-cell differentiation of the developing immune system: possible implications for the development of asthma and atopy. J. Allergy Clin. Immunol. 109: 923–928.
- 50 Barnes, P., G. Fitzgerald, M. Brown & C. Dollery. 1980. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N. Engl. J. Med. 303: 263–267.
- 51 Panina-Bordignon, P., D. Mazzeo, P.D. Lucia, et al. 1997. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100: 1513–1519.
- 52 Zieg, G., G. Lack, R.J. Harbeck, et al. 1994. In vivo effects of glucocorticoids on IgE production [see comments]. J. Allergy Clin. Immunol. 94: 222–230.
- 53 Coqueret, O., V. Lagente, C.P. Frere, et al. 1994. Regulation of IgE production by beta 2-adrenoceptor agonists. Ann. N.Y. Acad. Sci. 725: 44–49.
- 54 Segal, B.M., B.K. Dwyer & E.M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537–546.
- 55 Sternberg, E.M. 2001. Neuroendocrine regulation of autoimmune/inflammatory disease. J. Endocrinol. 169: 429–435.
- 56 Elenkov, I.J. & G.P. Chrousos. 2002. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. N.Y. Acad. Sci. 966: 290–303.
- 57 Sternberg, E.M., W.S. Young, R. Bernardini, et al. 1989. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc. Natl. Acad. Sci. USA 86: 4771–4775.
- 58 Sternberg, E.M., J.M. Hill, G.P. Chrousos, et al. 1989. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc. Natl. Acad. Sci. USA 86: 2374–2378.
- 59 Wilder, R.L. & I.J. Elenkov. 1999. Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Ann. N.Y. Acad. Sci. 876: 14–31.
- 60 Straub, R.H. & M. Cutolo. 2001. Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 44: 493–507.
